| Objective:To investigate the use of growth hormone(GH)in human Assisted Reproductive Technology(ART)in a retrospective cohort study.To investigate the effect of GH on pregnancy outcome of ART treatment in patients with polycystic ovary syndrome(PCOS),in order to seek a measure to improve pregnancy outcome,and to further evaluate the application value of GH in PCOS patients in ART treatment.Methods: A total of 162 infertility patients with polycystic ovary syndrome who received assisted reproductive technology in Reproductive Medicine Center,Yijishan Hospital,the First Affiliated Hospital of Wannan Medical College from June 2019 to June 2022 were selected,and the flexible antagonist program was used.Patients were divided into group A,experimental group(patients used growth hormone in the process of IVF-embryo transfer)and Group B,control group(patients did not use growth hormone in the process of IVF-embryo transfer)according to whether they were given growth hormone in the process of IVF-embryo transfer,which were subdivided into the following 6 groups: Group A1(normal weight group using growth hormone): 18.5≤BMI < 24kg/m2;Group B1(normal body weight control group): 18.5≤BMI < 24kg/m2;Group A2(overweight group using growth hormone): 24≤BMI < 28kg/m2;B2 group(overweight control group): 24≤BMI <28kg/m2;Group A3(obesity group using growth hormone): BMI≥28kg/m2;B3 group(obesity control group): BMI≥28kg/m2;The basic information of patients was analyzed,including age,infertility years,BMI,basic hormone levels,etc.The gonadotrophin(Gn)status of patients was analyzed: total Gn,number of days of Gn,ovum harvest and embryo harvest: number of ovum harvest,number of D3 transmissible embryos,number of highquality embryos,high-quality embryo rate and blastocyst formation rate.Collect laboratory data: Base serum follicle stimulating hormone(FSH),luteining hormone(LH),estradiol(E2),Testosterone,T),Anti-mullerian hormone(AMH)and serum FSH,LH,E2 and progesterone(P)on trigger day;The incidence of ovarian hyperstimulation syndrome,E2 and P on transplantation day,intima thickness on transplantation day,number of embryos transplanted,assisted pregnancy outcome of first frozen embryo transplantation,clinical pregnancy rate,twin rate,singlet rate,abortion rate,live birth rate,etc.,were compared in each group.Results:(1)There were no significant differences in age,duration of infertility,basal FSH,LH,E2,T,AMH,trigger day serum FSH,LH,E2 and P levels between the two groups(P>0.05).(2)There was no significant difference in the total amount of Gn and Gn days between A1 VS A2,B1 VS B2,A3 VS B3(P>0.05).(3)There was no significant difference in the number of oocytes obtained,the number of D3 transferable embryos,the number of high-quality embryos and the number of blastocysts formed between A1 group and A2 group(P>0.05),but there was significant difference in the rate of high-quality embryos formation between A1 group and A2 group(P<0.05).The rate of blastocyst formation in A1 group was higher than that in A2 group,but the difference was not statistically significant.There was no significant difference in the number of oocytes obtained,the number of transferable embryos,the number of high-quality embryos,the rate of high-quality embryos and the number of blastocysts formed between group B1 and group B2(P>0.05).The rate of blastocyst formation in group B1 was higher than that in group B2,but the difference was not statistically significant.There was no significant difference in the number of oocytes obtained,the number of transferable embryos,the number of high-quality embryos,the rate of high-quality embryos and the number of blastocysts formed between group A3 and group B3(P>0.05).The rate of blastocyst formation in group A3 was higher than that in group B3,but the difference was not statistically significant.(4)There were no significant differences in serum E2 and P levels on the day of the first frozen-thawed embryo transfer,the number of transferred embryos,and the endometrium on the day of transfer among the six groups(P>0.05).(5)There was no significant difference in the twin rate,singleton rate,abortion rate and live birth rate between group A1 and group A2(P>0.05),while the clinical pregnancy rate in group A1 was significantly higher than that in group A2(P<0.05).There were no significant differences in the twin rate,singleton rate,abortion rate,clinical pregnancy rate and live birth rate between group B1 and group B2(P>0.05).There was no significant difference in the twin rate,singleton rate,abortion rate and live birth rate between group A3 and group B3(P>0.05),while the clinical pregnancy rate in group A3 was significantly higher than that in group B3,the difference was statistically significant(P<0.05).Conclusion:1.The application of growth hormone in PCOS patients receiving antagonist regimen may improve the rate of high-quality embryo formation,especially for those with low BMI,the difference is statistically significant,while those with normal BMI and those with high BMI need to be expanded for further comparative study.2.The application of growth hormone may improve the blastocyst formation rate of PCOS patients receiving antagonist regimen,but the difference was not statistically significant,so the sample size can be expanded for further verification.3.The application of growth hormone may improve the clinical pregnancy rate of PCOS patients receiving the antagonist program to aid pregnancy,especially for patients with low and high BMI,there is a statistical difference,and the significance for patients with normal BMI can be further studied after increasing the sample size.4.The application of growth hormone in PCOS patients using antagonist to aid pregnancy is safe and reliable,without serious adverse reactions,and does not increase the abortion rate and risk of ovarian hyperstimulation.1.The application of growth hormone in PCOS patients receiving antagonist regimen may improve the rate of high-quality embryo formation,especially for those with low BMI,the difference is statistically significant,while those with normal BMI and those with high BMI need to be expanded for further comparative study.2.The application of growth hormone may improve the blastocyst formation rate of PCOS patients receiving antagonist regimen,but the difference was not statistically significant,so the sample size can be expanded for further verification.3.The application of growth hormone may improve the clinical pregnancy rate of PCOS patients receiving the antagonist program to aid pregnancy,especially for patients with low and high BMI,there is a statistical difference,and the significance for patients with normal BMI can be further studied after increasing the sample size. |
